Roche Blinks, But Is $93 Enough For Genentech Shareholders?
Executive Summary
Is $93 the magic number
You may also be interested in...
Blinding Them With Science: Genentech Tries To Win Shareholders Over
Genentech's March 2 presentation to analysts and investors - a four hour plus love-in dominated by talk of peptides and pathways - seems to have worked
Blinding Them With Science: Genentech Tries To Win Shareholders Over
Genentech's March 2 presentation to analysts and investors - a four hour plus love-in dominated by talk of peptides and pathways - seems to have worked
The Genentech Sales Pitch: Higher Values R Us
Despite a blizzard, Genentech attracts more than 300 Wall Street analysts and investors to hear why Roche’s bid undervalues the biotech.